A pill you swallow once a day fits into normal life more easily
Na corrida global para tratar a obesidade sem agulhas, a AstraZeneca apresenta resultados preliminares de um comprimido diário que promete o mesmo efeito dos injetáveis já consagrados. O elecoglipron, testado em 310 pacientes ao longo de até nove meses, reduziu o peso corporal em até 11,8% — números que ecoam os de medicamentos que se tornaram fenômenos culturais. A ciência avança, mas o mercado já tem donos, e o caminho até as farmácias ainda exige anos de evidências.
- Um comprimido diário produziu perda de peso comparável à das injeções semanais de semaglutida e tirzepatida, acendendo esperança para pacientes que evitam agulhas.
- Com apenas 310 participantes e menos de um ano de acompanhamento, os dados são promissores mas insuficientes — fases 3 mais amplas e longas são indispensáveis antes de qualquer aprovação regulatória.
- Novo Nordisk e Eli Lilly já ocupam o mercado com versões orais aprovadas nos EUA e na Europa, deixando a AstraZeneca na posição de retardatária em um setor que movimenta bilhões.
- O formato oral pode custar até sete vezes menos que os injetáveis, tornando o tratamento potencialmente acessível a uma parcela muito maior da população global.
A AstraZeneca deu um passo concreto em direção a um dos mercados mais disputados da medicina ao divulgar resultados de fase 2 do elecoglipron, um comprimido oral para obesidade. No estudo com 310 adultos com obesidade ou sobrepeso sem diabetes, os participantes que receberam a dose mais alta perderam em média 10,5% do peso corporal em seis meses — número que subiu para 11,8% ao final de nove meses. Os resultados foram publicados na segunda-feira no periódico The Lancet.
Os números importam porque se equiparam ao desempenho da semaglutida e da tirzepatida, os injetáveis vendidos como Ozempic e Mounjaro que transformaram o debate sobre obesidade nos últimos anos. Como esses medicamentos, o elecoglipron imita o hormônio GLP-1, que sinaliza ao cérebro para reduzir o apetite. A diferença está na forma: um comprimido tomado uma vez ao dia, sem agulhas, sem aplicações semanais. O perfil de segurança não apresentou surpresas.
Ainda assim, pesquisadores e a própria empresa reconhecem que o caminho até as prateleiras das farmácias é longo. Ensaios de fase 3 — maiores, mais longos e com milhares de pacientes — serão necessários para confirmar se a perda de peso se sustenta ao longo de anos e para detectar efeitos adversos que só emergem em populações maiores. A pesquisadora Marie Spreckley, da Universidade de Cambridge, destacou que essa etapa será decisiva para definir o papel do elecoglipron entre os tratamentos disponíveis.
O contexto competitivo torna o desafio ainda maior. A Novo Nordisk já vende uma versão oral do Wegovy nos Estados Unidos e obteve aprovação europeia em maio. A Eli Lilly lançou o Foundayo, aprovado nos EUA em abril. Ambas as empresas acumulam lucros expressivos e vantagem de pioneirismo. Para a AstraZeneca, o elecoglipron representa uma aposta em conveniência e custo — formulações orais podem ser até sete vezes mais baratas que os injetáveis — em um mercado que praticamente não existia há cinco anos e hoje movimenta bilhões. Os próximos ensaios dirão se essa aposta se transforma em presença real nas vidas dos pacientes.
AstraZeneca has moved closer to entering one of medicine's most competitive markets with early results from a mid-stage trial of an oral obesity pill. The drug, called elecoglipron, produced weight loss in line with injectable alternatives already on pharmacy shelves—a finding that could reshape how millions of people manage their weight if larger trials confirm what researchers observed in this smaller group.
The study involved 310 adults with obesity or excess weight but no diabetes. Over six months, those receiving the highest dose lost an average of 10.5 percent of their body weight. By nine months, that figure had climbed to 11.8 percent. These numbers matter because they match what patients achieve with semaglutida and tirzepatida, the injectable medications sold as Ozempic and Mounjaro that have become cultural touchstones in recent years. All three drugs work the same way: they mimic a natural hormone called GLP-1 that tells the brain to eat less and the body to burn more.
What sets elecoglipron apart is its form. It comes as a pill taken once daily, not a weekly injection. That convenience carries real weight in a market where patients often struggle with the needle itself, even when the medicine works. The safety profile was consistent with what doctors expect from this class of drugs—no surprises, no red flags that would derail further development. The results appeared Monday in The Lancet, one of medicine's most prestigious journals.
But this is only the beginning. Researchers and the company acknowledge that larger, longer trials are needed before anyone can prescribe elecoglipron. They must confirm the weight loss holds up over years, not months. They must watch for side effects that might only emerge in thousands of patients rather than hundreds. Dr. Marie Spreckley, an obesity researcher at Cambridge University, noted that phase 3 trials—the final stage before regulatory approval—will be essential to establish where this drug fits among the growing arsenal of obesity treatments.
AstraZeneca's timing is both promising and pressured. Two companies have already captured most of the market. Novo Nordisk, the Danish pharmaceutical giant, sells Wegovy as a pill in the United States and won European approval in May. Eli Lilly, the American manufacturer, got its oral version approved in the U.S. in April under the brand name Foundayo. Both companies moved fast, and both are reaping enormous profits. The oral formulations carry a particular advantage: they can cost up to seven times less than the injections they replace, making them far more accessible to patients who cannot afford weekly shots.
For AstraZeneca, success with elecoglipron would mark entry into a market that barely existed five years ago but now commands billions in annual sales. The company is betting that its pill can compete on convenience and cost even as rivals have already established themselves. The next phase will determine whether that bet pays off. Larger trials will begin soon, and the results will decide whether elecoglipron becomes another option in medicine cabinets or remains a footnote in the obesity treatment story.
Notable Quotes
The magnitude of weight loss observed with elecoglipron is comparable to results reported with other oral GLP-1 receptor agonists— The Lancet study
Phase 3 trials will be needed to confirm long-term persistence of effects, establish safety, and determine where this treatment fits among growing obesity and diabetes options— Dr. Marie Spreckley, Cambridge University
The Hearth Conversation Another angle on the story
Why does it matter that this is a pill instead of an injection? People manage injections for diabetes all the time.
True, but obesity treatment is different. These drugs are for people who don't have diabetes—they're healthy people trying to lose weight. The barrier to taking a weekly shot is higher when you're not already sick. A pill you swallow once a day fits into normal life more easily.
The weight loss numbers—10.5 to 11.8 percent—sound good, but is that actually significant?
It's meaningful. That's roughly 20 to 30 pounds for someone who weighs 200 pounds. It's enough to improve blood pressure, reduce joint stress, lower diabetes risk. But the study only ran nine months. We don't know if people keep the weight off or if it comes back once they stop taking it.
Why are the researchers so cautious about approving this? The results look solid.
Because 310 people in nine months is a small window. Obesity drugs need to work for years. You also need to know what happens when thousands of people take it—rare side effects that don't show up in hundreds of patients. The cautious language isn't doubt; it's how medicine actually works.
What's the real competition here? Is AstraZeneca behind?
Not behind—late. Novo Nordisk and Eli Lilly already have pills on the market. But the obesity market is enormous and growing. There's room for multiple players, especially if AstraZeneca's pill is cheaper or works better for certain patients. The race isn't over.
The cost difference—seven times cheaper—that seems like the real story.
It is. If elecoglipron costs a fraction of what Mounjaro costs, it changes who can access these drugs. Right now, cost keeps many people out. A cheaper pill could reach millions more. That's why the company is pushing forward.